News of the first takers of the desperately awaited Pfizer-BioNTech coronavirus vaccine spurred some hope and excitement amid new lockdowns and spiraling infections in much of the US and the UK. But in Russia, one of the few countries already offering vaccines to a wider segment of the general public, the turnout in the first two weeks of “large-scale” vaccination has been less than enthusiastic.